Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump’s move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump’s move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.